The efficacy of RC220 is still a risk - until proven otherwise. The fastest way to validate RC220 clinically would be 'Sheba 3.0'.
Unfortunately, Sheba 2.0 commenced prior to the bisantrene cardioprotection discovery in 2021. Both Clofarabine and Fludarabine (the Sheba 2.0 combination regime) have elicited cardiac damage / failure in patients.
A 'Sheba 3.0', undertaken correctly, has the potential to therapeutically validate RC220, FTO inhibition and cardioprotection.
https://www.jacc.org/doi/full/10.1016/j.jaccao.2019.09.007
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718929/
Ann: Race Board and Management Team Changes, page-446
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.000(0.00%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.35 | $254.2K | 185.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 212 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 5981 | 3 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |